LOXL3

Across TCGA pan-cancer cohorts, LOXL3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LOXL3 data layer compared with 23 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher LOXL3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LOXL3 expression acts as an unfavorable survival marker.

PDAC, UCEC, and LUAD are the cancer types where LOXL3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.474	0.898	<.001	71	view →
UCEC	DFS	Quartile	All	0.754	1.000	.006	22	view →
LUAD	OS	Quartile	All	0.730	0.928	.012	17	view →
CCRCC	DFS	Median	III,IV	0.399	0.932	.022	15	view →
LSCC	OS	Tertile	II,III,IV	0.743	0.957	.021	8	view →
GBM	OS	Quartile	All	0.262	0.536	.028	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LOXL3–PDAC (DFS)

Open the PDAC breakdown →